Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Oncol Lett. 2010 May;1(3):399-405. Epub 2010 May 1.

Melanoma biomarkers: Vox clamantis in deserto (Review).

Author information

  • 1Department of Internal Medicine, University of Missouri, Columbia, MO 65203.

Abstract

Detecting malignant melanoma at an early stage, monitoring therapy, predicting recurrence and identifying patients at risk for metastasis continue to be a challenging and demanding objective. The last two decades have witnessed innovations in the field of melanoma biomarkers. However, global agreement concerning monitoring and early detection has yet to be reached. This is a review of the current literature regarding melanoma biomarkers including demographic, clinical, pathological and molecular biomarkers that are produced by melanoma or non-melanoma cells. A number of these biomarkers demonstrate promising results as possible methods for early detection, predicting recurrence and monitoring therapy. Other biomarkers appear to be promising for identifying patients at risk for metastasis. We reviewed the most pertinent information in the field thus far and how this knowledge can impact, or not, the management of melanoma patients prognostically and therapeutically.

PMID:
22966315
[PubMed]
PMCID:
PMC3436446
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk